Biogen Buys Apellis for $5.6B to Expand Kidney DrugsBloomberg1 Apr 2026Duration: 1:46Read the full storyUp nextTrump Plans to Ease Limits on Tax-Exempt Diesel VarietyProbably Not Enough Money to Fix Paxton Campaign, Says MulvaneyRoundhill Launches S&P 500 Target 10,000 ETF'Spaghetti Cannon' Of ETFs: Corgi's Weniger3X Commodity ETFs: 'SEC Giving Market What It Wants'How Invesco Fights Off 'QQQ' Competition
